Abstract
This article critically examines current responses to multi-drug resistant tuberculosis (MDR-TB) and argues that bioethics needs to be willing to engage in a more radical critique of the problem than is currently offered. In particular, we need to focus not simply on market-driven models of innovation and anti-microbial solutions to emergent and re-emergent infections such as TB. The global community also needs to address poverty and the structural factors that entrench inequalities-thus moving beyond the orthodox medical/public health frame of reference.
Original language | English |
---|---|
Pages (from-to) | 107-113 |
Number of pages | 7 |
Journal | Journal of Bioethical Inquiry |
Volume | 12 |
Issue number | 1 |
DOIs | |
Publication status | Published - Mar 2015 |
Externally published | Yes |
Keywords
- Tuberculosis
- Radical critique
- Global health ethics
- Infectious disease
- Pharmaceutical industry
- Pharmaceutical industry